A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.
Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.
As Cepi asks for $2bn to fund development of a vaccine against coronavirus and Moderna moves into the clinic, Vantage takes a look at previous pandemic development costs.
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
The CS1 approach to treating multiple myeloma was once thought capable of matching CD38, but that train left the station some time ago.
The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.